0000000000423526

AUTHOR

J. Thompson

showing 6 related works from this author

Search for Production of Invisible Final States in Single-Photon Decays of Υ(1S)

2010

We search for single-photon decays of the Upsilon(1S) resonance, Upsilon->gamma+invisible, where the invisible state is either a particle of definite mass, such as a light Higgs boson A0, or a pair of dark matter particles, chi chi-bar. Both A0 and chi are assumed to have zero spin. We tag Upsilon(1S) decays with a dipion transition Upsilon(2S)->pi+pi-Upsilon(1S) and look for events with a single energetic photon and significant missing energy. We find no evidence for such processes in the mass range m_A0<=9.2 GeV and m_chi<=4.5 GeV in the sample of 98e6 Upsilon(2S) decays collected with the BaBar detector and set stringent limits on new physics models that contain light dark ma…

Particle physicsPhotonAstrophysics::High Energy Astrophysical PhenomenaPhysics beyond the Standard ModelElectron–positron annihilationDark matterFOS: Physical sciencesGeneral Physics and Astronomy01 natural sciencesResonance (particle physics)High Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)PACS: 13.20.Gd 12.60.Jv 14.80.Da 95.35.+d0103 physical sciencessingle-photon decays of Upsilon(1S)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsLight dark matterPhysicsMissing energy010308 nuclear & particles physicsParticle physicsBABAR detectorHEPBaBarHiggs bosonHigh Energy Physics::ExperimentFísica de partículesExperimentsBaBar detector at SLAC
researchProduct

Association Between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib Plus Best Supportive Care (BS…

2012

ABSTRACT Background Tumor EGFR and KRas mutations are both predictive and prognostic biomarkers in patients with advanced NSCLC. We analyzed the correlation between these biomarkers and treatment outcomes in a phase III trial of 3rd/4th line sorafenib in patients with NSCLC. Methods The global, randomized, placebo-controlled MISSION trial enrolled 703 patients with advanced relapsed/refractory NSCLC of predominantly non-squamous histology. The primary study endpoint was overall survival (OS). EGFR and KRas mutations were analyzed in archival tumor samples and in circulating tumor DNA isolated from plasma. Results Tumor and/or plasma mutation data were available from 347 patients (49%). EGFR…

OncologySorafenibmedicine.medical_specialtyProportional hazards modelbusiness.industryHematologymedicine.disease_causePlacebomedicine.diseaseBreast cancerOncologyEgfr mutationInternal medicineMedicineBiomarker (medicine)KRASStage (cooking)businessmedicine.drugAnnals of Oncology
researchProduct

tt¯production cross section inpp¯collisions ats=1.8TeV

2003

PhysicsNuclear and High Energy PhysicsCross section (physics)Particle physics010308 nuclear & particles physics0103 physical sciencesProduction (computer science)010306 general physics01 natural sciencesPhysical Review D
researchProduct

Search forBs0→μ+μ−andB0→μ+μ−Decays with CDF II

2011

A search has been performed for B{sub s}{sup 0} {yields} {mu}{sup +}{mu}{sup -} and B{sup 0} {yields} {mu}{sup +}{mu}{sup -} decays using 7 fb{sup -1} of integrated luminosity collected by the CDF II detector at the Fermilab Tevatron collider. The observed number of B{sup 0} candidates is consistent with background-only expectations and yields an upper limit on the branching fraction of {Beta}(B{sup 0} {yields} {mu}{sup +}{mu}{sup -}) < 6.0 x 10{sup -9} at 95% confidence level. We observe an excess of B{sub s}{sup 0} candidates. The probability that the background processes alone could produce such an excess or larger is 0.27%. The probability that the combination of background and the expe…

Flight directionNuclear and High Energy PhysicsParticle physicsMesonTevatronGeneral Physics and Astronomy01 natural sciences7. Clean energyLuminosityStandard Modellaw.inventionNuclear physicsParticle decaychemistry.chemical_compoundlawTheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITY0103 physical sciencesInvariant massLimit (mathematics)FermilabCollider010306 general physicsPhysicsMuon010308 nuclear & particles physicsBranching fractionSupersymmetryD0 experimentIMesCrystallographychemistryDecay lengthHigh Energy Physics::ExperimentLeptonPhysical Review Letters
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct

Measurement of thett¯production cross section inpp¯collisions ats=1.96  TeVusing soft electronb-tagging

2010

The authors present a measurement of the t{bar t} production cross section using events with one charged lepton and jets from p{bar p} collisions at a center-of-mass energy of 1.96 TeV. A b-tagging algorithm based on the probability of displaced tracks coming from the event interaction vertex is applied to identify b quarks from top decay. Using 318 pb{sup -1} of data collected with the CDF II detector, they measure the t{bar t} production cross section in events with at least one restrictive (tight) b-tagged jet and obtain 8.9{sub -1.0}{sup +1.0}(stat.){sub -1.0}{sup +1.1}(syst.) pb. The cross section value assumes a top quark mass of m{sub t} is presented in the paper. This result is cons…

Top quarkCollider physicsHadronTevatronGeneral Physics and AstronomyElementary particleKinematicsElectronJet (particle physics)01 natural sciences7. Clean energyParticle identificationlaw.inventionlawInvariant massFermilabNuclear ExperimentQuantum chromodynamicsPhysicsLarge Hadron ColliderLuminosity (scattering theory)Supersymmetryb-taggingHadronizationTransverse planeProduction (computer science)Collider Detector at FermilabQuarkSemileptonic decayNuclear and High Energy PhysicsParticle physicsBar (music)Astrophysics::High Energy Astrophysical PhenomenaBottom quarkMeasure (mathematics)Standard ModelNuclear physicsCross section (physics)Particle decay0103 physical sciencesCollider010306 general physicsCompact Muon SolenoidMuonBranching fraction010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyMultiplicity (mathematics)FermionVertex (geometry)Pair productionHigh Energy Physics::ExperimentEnergy (signal processing)Bar (unit)LeptonPhysical Review D
researchProduct